Autologous adipose derived mesenchymal stem cells - Hope Biosciences
Alternative Names: Autologous HB-adMSCs; HB adMSCs; HB-adMSCLatest Information Update: 01 Jul 2024
At a glance
- Originator Hope Biosciences
- Developer Hope Biosciences; University of Texas Health Science Center at Houston
- Class Antineoplastics; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections; Multiple sclerosis
- Phase I/II Alzheimer's disease; Musculoskeletal pain; Rheumatoid arthritis; Traumatic brain injuries
- Preclinical Glioblastoma
- No development reported Cerebral palsy; Huntington's disease; Osteoarthritis; Parkinson's disease; Prostate cancer; Spinal cord injuries; Stroke; Thrombotic thrombocytopenic purpura
Most Recent Events
- 04 Jun 2024 Hope Biosciences Stem Cell Research Foundation completes the phase-II clinical trials in Multiple sclerosis in USA (IV) (NCT05116540)
- 31 May 2024 Efficacy and adverse events data from phase II HBPCOVID02 trial in COVID-2019 infections was released by Hope Biosciences
- 02 Apr 2024 Hope Biosciences completes phase II HBPCOVID02 trial for COVID-2019 infections in USA (IV) (NCT05126563)